Condition
Suggested Conditions
- Anxiety
- Depression
- Alzheimer's Disease
- Weight Loss
- Heart Disease
- Cancer
- Asthma
Location
Search Clinical Trials
Conditions
Locations
Treatment Type
Trial Phase
Trial Status
Paid Participation
88 Glioblastoma Trials near Boston, MA
Power is an online platform that helps thousands of Glioblastoma patients discover FDA-reviewed trials every day. Every trial we feature meets safety and ethical standards, giving patients an easy way to discover promising new treatments in the research stage.
Learn More About PowerOptune + Temozolomide + Pembrolizumab for Brain Cancer
Boston, Massachusetts
This is a multicenter, two-arm, randomized, double-blind, placebo-controlled study of Optune® (Tumor Treating Fields at 200 kHz) together with maintenance Temozolomide (TMZ) chemotherapy agent and pembrolizumab compared to Optune® together with maintenance TMZ and placebo in newly diagnosed Glioblastoma (GBM) patients. The primary objective of the study is to evaluate the Overall Survival (OS).
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Immunodeficiency, Pneumonitis, Other Malignancy, Others
Must Be Taking:Temozolomide
741 Participants Needed
Niraparib vs Temozolomide for Brain Cancer
Boston, Massachusetts
The goal of this Phase 3 clinical trial is to compare the efficacy of niraparib versus temozolomide (TMZ) in adult participants with newly-diagnosed, MGMT unmethylated glioblastoma multiforme (GBM). The main questions it aims to answer are:
Does niraparib improve progression-free survival (PFS) compared to TMZ?
Does niraparib improve overall survival (OS) compared to TMZ?
Participants will be randomly assigned to one of two treatment arms: niraparib or TMZ.
* study drug (Niraparib) or
* comparator drug (Temozolomide - which is the standard approved treatment for MGMT unmethylated glioblastoma).
The study medication will be taken daily while receiving standard of care radiation therapy (RT) for 6-7 weeks.
Participants may continue to take the niraparib or TMZ adjuvantly as long as the cancer does not get worse or completion of 6 cycles of treatment (TMZ). A total of 450 participants will be enrolled in the study.
Participants' tasks will include:
* Complete study visits as scheduled
* Complete a diary to record study medication
No Placebo Group
Prior Safety Data
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 3
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Pneumonitis, Cirrhosis, Others
Must Not Be Taking:PARP Inhibitors
450 Participants Needed
Multiple Therapies for Glioblastoma
Boston, Massachusetts
This trial is testing various treatments for patients with newly diagnosed or returning brain cancer. It adjusts treatments based on how well patients are doing to find the most effective options. The goal is to improve survival rates by matching the best treatments to specific patient types.
No Placebo Group
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2, 3
Key Eligibility Criteria
Disqualifiers:Leptomeningeal Disease, QTc Prolongation, Others
Must Not Be Taking:Carmustine, Lomustine, Bevacizumab, Others
1280 Participants Needed
Temozolomide + Veliparib for Glioblastoma
Boston, Massachusetts
This randomized phase II/III trial studies how well temozolomide and veliparib work compared to temozolomide alone in treating patients with newly diagnosed glioblastoma multiforme. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Veliparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. It is not yet known whether temozolomide is more effective with or without veliparib in treating glioblastoma multiforme.
Pivotal Trial (Near Approval)
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2, 3
Key Eligibility Criteria
Disqualifiers:Uncontrolled Seizures, Thromboembolic Disease, Others
Must Be Taking:Temozolomide
447 Participants Needed
Dabrafenib + Trametinib for Brain Tumors
Boston, Massachusetts
This trial is studying the effects of two cancer medications, dabrafenib and trametinib, in children. These drugs work by stopping signals that make cancer cells grow. Dabrafenib and trametinib have shown benefits in various BRAF-mutant tumors, including melanoma, lung cancer, and thyroid cancer. The goal is to see how these treatments affect children over time.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 4
Age:1 - 99
Key Eligibility Criteria
Disqualifiers:Severe Toxicities, Others
Must Be Taking:Dabrafenib, Trametinib
163 Participants Needed
Intensified Radiation Therapy for Brain Cancer
Boston, Massachusetts
Glioblastoma (GBM) is an aggressive malignancy of the central nervous system. Older adults with GBM have a unique constellation of medical, psychosocial, and supportive care needs. To address these challenges, prior work has evaluated the feasibility of hypofractionation, a treatment approach delivering fewer, larger radiation dosages over a shorter time period. Common hypofractionated regimens deliver a lower biologically equivalent radiation dose than the conventional regimens used for younger adults. Whether dose escalated hypofractionation can further improve outcomes in older adults remains unclear.
This will be a hybrid randomized control trial comparing the efficacy and safety of dose-escalated and standard hypofractionated radiotherapy among older adults with newly-diagnosed glioblastoma compared to standard three-week course. This research study involves the administration of radiation therapy. Radiation will either be delivered at the standard daily dose or at an increased daily dose over a three weeks course of radiation treatment.
Research study procedures will include a screening evaluation to assess eligibility, as well as clinical visits for radiation delivery and to assess symptoms during treatment and at scheduled follow-up times.
Participants will be randomly assigned to one of the two arms of the trial:
1. Standard hypofractionated radiation over 3 weeks
2. Dose-escalated hypofractionated radiation over 3 weeks
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Age:65+
Key Eligibility Criteria
Disqualifiers:Recurrent Glioma, Other CNS Malignancies, Serious Infection, Others
Must Not Be Taking:Investigational Cancer Drugs
56 Participants Needed
L19TNF + Lomustine for Glioblastoma
Boston, Massachusetts
The trial aims to collect safety, efficacy, exposure, dose- response, pharmacokinetic and pharmacodynamic information of the combination of L19TNF and lomustine at different dose levels in patients with Glioblastoma at progression or recurrence
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Heart Disease, Others
Must Not Be Taking:Anticoagulants, Immunosuppressants
90 Participants Needed
Pembro + Olaparib with TMZ for Recurrent Glioblastoma
Boston, Massachusetts
This trial is testing a combination of three drugs to treat brain tumors that have come back after previous treatments. The drugs help the immune system attack the tumor, stop the tumor cells from repairing themselves, and prevent them from growing. About 66-78 people will participate in this study.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:IDH Mutation, Brainstem Tumor, Others
Must Not Be Taking:PARP Inhibitors, Anti-VEGF Agents
78 Participants Needed
BPM31510 + Vitamin K1 for Glioblastoma
Boston, Massachusetts
This is a single-arm, non-randomized, open-label Phase 2 therapeutic study that will assess the effects of adding BPM31510 onto a conventional treatment framework of RT and concurrent TMZ chemotherapy for subjects with newly diagnosed glioblastoma.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Cerebral Hemorrhage, Cardiac History, Coagulopathies, Others
Must Not Be Taking:Anticoagulants, Digitalis, Antiangiogenics, Theophylline
50 Participants Needed
Combination Immunotherapy for Glioblastoma
Boston, Massachusetts
The purpose of this study is to assess progression-free survival (PFS) and overall survival (OS) in newly diagnosed Glioblastoma (GBM) participants treated with IGV-001 as compared with placebo.
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Bi-hemispheric Disease, Cardiac Disease, Others
Must Not Be Taking:Investigational Agents, Tumor Treating Fields
93 Participants Needed
GBM Vaccine for Glioblastoma
Boston, Massachusetts
This trial is testing a new vaccine called VBI-1901 for patients whose brain cancer, glioblastoma, has returned. The vaccine aims to help the immune system recognize and fight the cancer cells. Researchers are checking if the vaccine is safe and finding the best dose to use.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Active Infection, Cancer History, Autoimmune, Others
Must Not Be Taking:Immunosuppressants, Antivirals
98 Participants Needed
Abemaciclib for Glioblastoma
Boston, Massachusetts
This research study is studying a targeted therapy as a possible treatment for recurrent glioblastoma (GBM).
The following intervention will be used in this study:
-Abemaciclib
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:1p/19q Co-deletion, IDH1/2 Mutation, Others
Must Not Be Taking:CDK4/6 Inhibitors, Anti-VEGF Agents
45 Participants Needed
Multiple Drug Therapy for Glioblastoma
Boston, Massachusetts
This research study is studying several investigational drugs as a possible treatment for Glioblastoma (GBM).
The drugs involved in this study are :
* Abemaciclib (arm is currently closed to accrual)
* Temozolomide (temodar)
* Neratinib (arm is currently closed to accrual)
* CC115 (arm is currently closed to accrual)
* QBS10072S
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Cardiac Disease, Diabetes, Infection, Others
Must Not Be Taking:EIAEDs, CYP3A Drugs
460 Participants Needed
NMS-03305293 + Temozolomide for Glioblastoma
Boston, Massachusetts
Multicenter, open-label, single-arm Phase 1/2 study on the safety and efficacy of the combination of NMS-03305293 and temozolomide (TMZ) in adult patients with diffuse gliomas (Phase 1) and isocitrate dehydrogenase (IDH) wild type glioblastoma (Phase 2) at first relapse.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Active Infections, Heart Failure, Others
Must Not Be Taking:Anticancer Agents, PARP Inhibitors
150 Participants Needed
Clindamycin + Triamcinolone for Glioblastoma Skin Side Effects
Boston, Massachusetts
The participants are being treated with Tumor Treating Fields (TTFields) for malignant glioma, and this type of treatment may cause skin-related side effects. This study will test whether using clindamycin and triamcinolone topical lotions can prevent skin-related side effects of TTFields.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Scalp Disorders, Infection, Pregnancy, Others
Must Not Be Taking:Topical Therapies, Antibiotics, Dexamethasone
48 Participants Needed
Dabrafenib + Trametinib After Radiation for Brain Cancer
Boston, Massachusetts
This trial studies how well dabrafenib and trametinib work after radiation therapy in children and young adults with a specific type of brain tumor. These drugs help stop tumor growth by blocking signals that tell the cells to multiply. Dabrafenib has been developed and tested extensively for a specific type of skin cancer, showing effectiveness both alone and when used with trametinib.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:3 - 25
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Cardiac Disease, Others
Must Not Be Taking:Chemotherapy, Immunotherapy, Antidepressants, Others
58 Participants Needed
Veliparib + Radiation + Temozolomide for Brain Cancer
Boston, Massachusetts
This phase II trial studies how well veliparib, radiation therapy, and temozolomide work in treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600 mutations. Poly adenosine diphosphate (ADP) ribose polymerases (PARPs) are proteins that help repair DNA mutations. PARP inhibitors, such as veliparib, can keep PARP from working, so tumor cells can't repair themselves, and they may stop growing. Radiation therapy uses high energy x-rays to kill tumor cells and shrink tumors. Drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving veliparib, radiation therapy, and temozolomide may work better in treating patients with newly diagnosed malignant glioma without H3 K27M or BRAFV600 mutations compared to radiation therapy and temozolomide alone.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Age:3 - 25
Key Eligibility Criteria
Disqualifiers:Diffuse Astrocytoma, Oligodendrogliomas, PXA, Others
Must Not Be Taking:Anti-cancer Agents
38 Participants Needed
Combination Immunotherapy + Chemoradiation for Glioblastoma
Boston, Massachusetts
Phase 1/2 trial to evaluate safety, immunogenicity and preliminary efficacy of INO-5401 and INO-9012 in combination with cemiplimab (REGN2810), with radiation and chemotherapy, in subjects with newly-diagnosed glioblastoma (GBM).
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Immunodeficiency, Others
Must Not Be Taking:PD-1 Inhibitors, Idelalisib
52 Participants Needed
Nivolumab + Bevacizumab for Glioblastoma
Boston, Massachusetts
The purpose of this study is to test the effectiveness (how well the drug works), safety and tolerability of an investigational drug called nivolumab (also known as BMS-936558) in glioblastoma (a malignant tumor, or GBM), when added to bevacizumab.
Nivolumab is an antibody (a kind of human protein) that is being tested to see if it will allow the body's immune system to work against glioblastoma tumors. Opdivo (nivolumab ) is currently FDA approved in the United States for melanoma (a type of skin cancer), non-small cell lung cancer, renal cell cancer (a type of kidney cancer), Hodgkin's lymphoma but is not approved in glioblastoma. nivolumab may help your immune system detect and attack cancer cells.
Bevacizumab is a drug which works on the blood vessel that supply the tumor and potentially can starve the tumor by cutting off the blood supply to these tumors. Bevacizumab is commercially available and FDA approved for individuals with recurrent glioblastoma.
This study has two study groups. Arm 1 will receive the study drug nivolumab 240mg and bevacizumab 10 mg (standard dose) every 2 weeks and Arm 2 will receive the study drug nivolumab 240 mg and bevacizumab 3 mg (low dose) every 2 weeks. A process will be used to assign participants, by chance, to one of the study groups. Neither participants nor doctors can choose which group participants are in. This is done by chance because no one knows if one study group is better or worse than the other. 90 total participants are expected to participate in this study (45 participants in each arm).
Your total participation in this study from the time you have signed the informed consent to your last visit, including follow-up visits, may be more than three years (depending on what effect the treatment has on your cancer, and how well you tolerate the treatment).
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Autoimmune Disease, Hypertension, Cardiovascular Disease, Others
Must Not Be Taking:Anticoagulants, Corticosteroids, Immunosuppressants, Others
90 Participants Needed
Olaparib for Advanced Cancer
Boston, Massachusetts
This phase II trial studies how well olaparib works in treating patients with glioma, cholangiocarcinoma, or solid tumors with IDH1 or IDH2 mutations that has spread from where it first started (primary site) to other places in the body (metastatic) and that does not respond to treatment (refractory). Olaparib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Other Malignancy, Brain Metastases, Others
Must Not Be Taking:CYP3A Inhibitors, CYP3A Inducers
89 Participants Needed
Why Other Patients Applied
"I've tried several different SSRIs over the past 23 years with no luck. Some of these new treatments seem interesting... haven't tried anything like them before. I really hope that one could work."
ZS
Depression PatientAge: 51
"As a healthy volunteer, I like to participate in as many trials as I'm able to. It's a good way to help research and earn money."
IZ
Healthy Volunteer PatientAge: 38
"My orthopedist recommended a half replacement of my right knee. I have had both hips replaced. Currently have arthritis in knee, shoulder, and thumb. I want to avoid surgery, and I'm open-minded about trying a trial before using surgery as a last resort."
HZ
Arthritis PatientAge: 78
"I have dealt with voice and vocal fold issues related to paralysis for over 12 years. This problem has negatively impacted virtually every facet of my life. I am an otherwise healthy 48 year old married father of 3 living. My youngest daughter is 12 and has never heard my real voice. I am now having breathing issues related to the paralysis as well as trouble swallowing some liquids. In my research I have seen some recent trials focused on helping people like me."
AG
Paralysis PatientAge: 50
"I was diagnosed with stage 4 pancreatic cancer three months ago, metastatic to my liver, and I have been receiving and responding well to chemotherapy. My blood work revealed that my tumor markers have gone from 2600 in the beginning to 173 as of now, even with the delay in treatment, they are not going up. CT Scans reveal they have been shrinking as well. However, chemo is seriously deteriorating my body. I have 4 more treatments to go in this 12 treatment cycle. I am just interested in learning about my other options, if any are available to me."
ID
Pancreatic Cancer PatientAge: 40
Cediranib + Olaparib vs Bevacizumab for Recurrent Glioblastoma
Boston, Massachusetts
This trial compares two treatments for patients with glioblastoma that has returned. One treatment uses pills that block enzymes needed for tumor growth. The other treatment uses an IV drug that helps the immune system fight cancer and prevents tumors from growing. The goal is to see which treatment works better at stopping the cancer from progressing.
No Placebo Group
Prior Safety Data
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Hypertension, Myocardial Infarction, HIV, Others
Must Not Be Taking:PARP Inhibitors, VEGF Pathway
70 Participants Needed
ACP-196 for Glioblastoma
Boston, Massachusetts
A Phase 1b/2, Multicenter, Open-Label Study of ACP-196 in Subjects with Recurrent Glioblastoma Multiforme (GBM)
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1, 2
Key Eligibility Criteria
Disqualifiers:Significant Cardiovascular Disease, Others
Must Be Taking:Anticonvulsants
24 Participants Needed
Vaccine Therapy + Temozolomide for Glioblastoma
Boston, Massachusetts
This trial studies how well a special vaccine works with a common chemotherapy drug in treating patients with recently found brain cancer. The vaccine helps the immune system fight the cancer, while the chemotherapy attacks the cancer cells directly.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Pregnancy, Autoimmune Disorder, HIV/AIDS, Others
Must Be Taking:Temozolomide
66 Participants Needed
High-Dose Radiation + Temozolomide for Glioblastoma
Boston, Massachusetts
This randomized phase II trial studies how well dose-escalated photon intensity-modulated radiation therapy (IMRT) or proton beam radiation therapy works compared with standard-dose radiation therapy when given with temozolomide in patients with newly diagnosed glioblastoma. Radiation therapy uses high-energy x-rays and other types of radiation to kill tumor cells and shrink tumors. Specialized radiation therapy that delivers a high dose of radiation directly to the tumor may kill more tumor cells and cause less damage to normal tissue. Drugs, such as temozolomide, may make tumor cells more sensitive to radiation therapy. It is not yet known whether dose-escalated photon IMRT or proton beam radiation therapy is more effective than standard-dose radiation therapy with temozolomide in treating glioblastoma.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Prior Invasive Malignancy, Others
Must Be Taking:Temozolomide
606 Participants Needed
ERC1671 + GM-CSF + Cyclophosphamide for Glioblastoma
Boston, Massachusetts
This phase II clinical trial studies how well ERC1671 plus Granulocyte-macrophage colony-stimulating factor (GM-CSF) plus Cyclophosphamide with Bevacizumab works compared to Placebo Injection plus Placebo Pill with Bevacizumab in treating patients with recurrent/progressive, bevacizumab naïve glioblastoma multiforme and gliosarcoma (World Health Organization (WHO) grade IV malignant gliomas, GBM).
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Metastatic Disease, Active Infection, Uncontrolled Hypertension, Others
Must Not Be Taking:Immunosuppressants, Bevacizumab
84 Participants Needed
Sacituzumab Govitecan for Glioblastoma
Boston, Massachusetts
This trial is testing a new treatment or drug on all patients in the study to see if it is effective and safe.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 2
Key Eligibility Criteria
Disqualifiers:Hypertension, Cardiac Arrhythmias, Infection, Others
Must Not Be Taking:Bevacizumab, Warfarin, Enzyme-inducing Antiepileptics
32 Participants Needed
CUE-102 for Glioblastoma
Boston, Massachusetts
The goal of this study is to evaluate the safety of the experimental drug, CUE-102, and establish the recommended dose of CUE-102 for participants with Recurrent Glioblastoma (GBM).
The name of the study drug involved in this study is:
-CUE-102 (a type of fusion protein)
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Immunodeficiency, Active Infection, Cardiovascular Disease, Others
Must Not Be Taking:Immunosuppressants, Anticoagulants
18 Participants Needed
Troriluzole for Recurrent Brain Cancer
Boston, Massachusetts
This research study is studying troriluzole as a possible treatment for recurrent glioblastoma.
The name of the study drug involved in this research study is:
-Troriluzole (a tripeptide prodrug of riluzole)
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Early Phase 1
Key Eligibility Criteria
Disqualifiers:Leptomeningeal Disease, Hepatitis, HIV, Others
Must Not Be Taking:CYP1A2 Inhibitors, Anti-glutamergic Agents
27 Participants Needed
[177Lu]Lu-NeoB for Glioblastoma
Boston, Massachusetts
This study will investigate different doses of \[177Lu\]Lu-NeoB in combination with RT and TMZ in participants with newly diagnosed glioblastoma, with methylated or unmethylated promoter, to assess the safety and efficacy of \[177Lu\]Lu-NeoB in combination with the SoC and in recurrent glioblastoma as single agent, to identify the recommended dose and to also explore the safety of the PET imaging agent \[68Ga\]Ga-NeoB and characterize its uptake in the tumor area.
No Placebo Group
Trial Details
Trial Status:Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Cardiac Disease, Other Malignancy, Others
Must Not Be Taking:QT-prolonging Drugs
48 Participants Needed
ITI-1001 for Glioblastoma
Boston, Massachusetts
This trial tests a new vaccine for brain cancer. It targets patients with newly diagnosed glioblastoma. The vaccine aims to help the immune system fight the cancer. The treatment has been shown to be safe and feasible in previous studies.
No Placebo Group
Trial Details
Trial Status:Active Not Recruiting
Trial Phase:Phase 1
Key Eligibility Criteria
Disqualifiers:Pregnancy, HIV, Cardiac Arrhythmia, Others
Must Be Taking:Chemoradiation, TMZ
10 Participants Needed
Know someone looking for new options?
Spread the word